← Eichor
Condition: Graft Versus Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Graft Versus Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens
Phase 2/Phase 3 · 56 location(s) · University Hospital, Angers · NCT02416388Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet
Phase 1/Phase 2 · 2 location(s) · National Cancer Institute (NCI) · NCT05436418Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT07238712Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HS
Phase N/A · 1 location(s) · Ciceri Fabio · NCT05124288High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Phase N/A · 1 location(s) · Yigeng Cao,MD,PhD · NCT07205523A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07183878Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantati
Phase 1 · 1 location(s) · Sawa Ito, MD · NCT07565220ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 · 1 location(s) · Leland Metheny · NCT06680661Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
Phase 2 · 1 location(s) · Hannah Choe, MD · NCT07249346Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00106925Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
NA · 7 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT03439371PTCy and ATG for MSD and MUD Transplants
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06299462Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT07566377Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 · 1 location(s) · Jonathan Brammer · NCT07356245Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00001529Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT03555851Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myel
Phase 2 · 3 location(s) · Fred Hutchinson Cancer Center · NCT03970096Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06815003Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adul
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06128070
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.